Jingfeng Medical (02675.HK) said its board plans to use a general mandate approved at a shareholders’ meeting on June 16, 2025, to repurchase H shares in the open market, subject to market conditions.
According to Jin10, the company said the buyback authorization would allow repurchases of up to a total of HK$200 million worth of H shares.
The company said the repurchases could be carried out from time to time and would remain effective until the conclusion of the next annual general meeting, or until the repurchase mandate is revoked or amended by a special resolution.
STOCKS | Jingfeng Medical Plans Up to HK$200 Million H-Share Buyback
2026-06-09 12:38:30
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
